Skip to main content

Vincristine sulfate liposome injection

Details of the Drug
Generic Name:
Vincristine sulfate liposome injection
Pronunciation:
vin-KRIS-teen SUHL-feyt
Drug Type:
Antimitotic  
How the Drug is Given:

Intravenously (IV) (fatal if given by other routes)

Names:
Marqibo®
Vincristine sulfate liposome injection

Indications and Usage

Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

Side effects needing medical attention

Constipation; bowel obstruction; nausea; fever; fatigue; diarrhea; decreased appetite; insomnia; low blood cell counts; pneumonia; life-threatening low blood pressure; infection; peripheral sensory and motor neuropathy; lack of strength; muscular weakness; respiratory distress; respiratory failure; pain; abdominal pain; hypotension; mental status changes; cardiac arrest.  

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.